News

Blog | 9.3.18

Financing the Hunt

Drug hunters beware, this battle is not for the faint of heart. Aleks Engel of Novo Holdings is helping us understand why the antibiotic discovery business model is broken, and what we can do about it. He also highlights the companies that have run away, and those that are valiantly staying in the game. I remember not so long ago that the hunt for new Ebola drugs was similarly affected – and how shortsighted that then seemed when the virus washed up on Texas shores. Glad there are organizations like Novo Holdings and CARB-X that are filling the gaps.